Curewin-Hylico Pharma Private Limited, a active private limited company, was established on 05 December 2014 in Hyderabad, Telangana, India. Engaging in drug formulation & development within the trade sector, it holds CIN: U51101TG2014PTC096702. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹5.00 Cr and a paid-up capital of ₹4.41 Cr.
It upholds a compliant status. Employing 82 professional, Its leadership includes Srinivas Lagisetty (Director), Madhavaram Ravinder Rao (Director), Babu Uttam Kumar Rao Julapalli (Director). Past directors included Madhavaram Ravinder Rao, Neelesh Rao Julapally, Babu Uttam Kumar Rao Julapalli. It holds ₹1.32 Cr open charges and ₹5.00 M settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at H No.8-2-310/B/33, Plot No.33, Ground Floor House No.266, Road No.14, Banjara Hills, Hyderabad, Telangana, 500034.
U51101TG2014PTC096702
096702
05 December 2014
₹5.00 Cr
₹4.41 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Curewin-Hylico Pharma Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Srinivas Lagisetty | Director | 05 Dec 2014 | Current |
| Madhavaram Ravinder Rao | Director | 28 Apr 2018 | Current |
| Babu Uttam Kumar Rao Julapalli | Director | 12 Apr 2015 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 29 Sep 2018 | Past |
| Pramod Abcsdd | Director | 07 Feb 2024 | Past |
| Pramod Abcsdd | Additional Director | 26 Aug 2015 | Past |
| Pramod Abcsdd | Managing Director | 25 Sep 2020 | Past |
| Pramod Abcsdd | Director | 27 Jan 2018 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Curewin-Hylico Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 12.18% decrease. The company also saw a substantial improvement in profitability, with a 153.07% increase in profit. The company's net worth Soared by an impressive increase of 70.97%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Curewin-Hylico Pharma had a public holding of 46.86%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹13,214,772.00
₹5,000,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Dec 2024 | Hdfc Bank Limited | ₹1.02 M | Open |
| 19 Mar 2022 | Axis Bank Limited | ₹1.00 Cr | Open |
| 19 Jan 2022 | Hdfc Bank Limited | ₹2.20 M | Open |
| 04 Sep 2020 | Hdfc Bank Limited | ₹5.00 M | Satisfied |
Explore comprehensive loan charge details -
Curewin-Hylico Pharma has a workforce of 82 employees as of Mar 21, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Curewin-Hylico Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Curewin-Hylico Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity A charge registered on 04 Sep 2020 via Charge ID 100374366 with Hdfc Bank Limited was fully satisfied on 27 Jan 2025. was completed.
The activity A charge with Hdfc Bank Limited amounted to Rs. 0.10 Cr with Charge ID 101022876 was registered on 21 Dec 2024. was completed.
The activity Curewin-Hylico Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Curewin-Hylico Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad. was recorded as a recent event.
The activity A charge with Axis Bank Limited amounted to Rs. 1.00 Cr with Charge ID 100554590 was registered on 19 Mar 2022. was completed.
A charge with Hdfc Bank Limited amounted to Rs. 0.22 Cr with Charge ID 100534993 was registered on 19 Jan 2022. was recorded as a recent event.
The CIN of Curewin-Hylico Pharma Private Limited is U51101TG2014PTC096702.
Curewin-Hylico Pharma Private Limited is headquartered at H No.8-2-310/B/33, Plot No.33, Ground Floor House No.266, Road No.14, Banjara Hills, Hyderabad, Telangana, 500034.
Curewin-Hylico Pharma Private Limited was incorporated on 05 December 2014.
The current directors of Curewin-Hylico Pharma Private Limited are
The primary industry of Curewin-Hylico Pharma Private Limited is Trade.
Curewin-Hylico Pharma Private Limited is unlisted.
The authorized capital of Curewin-Hylico Pharma Private Limited is ₹5.00 Cr, and the paid-up capital is ₹4.41 Cr.
The compliance status of Curewin-Hylico Pharma Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX